All In Biotech

Drug Trial Radar · NCT07499440

Safety and Efficacy of HB-1 for Post-Traumatic Stress Disorder

Safety and Efficacy of HB-1 for PTSD: A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jun 3, 2026

Primary completion

Sep 2027

Study completion Oct 2027

Sponsor

Lead sponsor
HB BioTech, LLCIndustry
Sponsor type
Industry
First posted
Mar 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo in male and female adult patients aged 18 to 65 years, inclusive, with Post-Traumatic Stress Disorder (PTSD).

Conditions

  • PTSD
  • Mental Illness

Interventions

  • HB-1Drug

    HB-1 will be supplied as a dual active pharmaceutical ingredient tablet. The two HB-1 doses for this study include 64/192 and 86/258 telmisartan/verapamil extended release, using unique bi-layer tablets. All subjects randomized to receive HB-1 will begin with the 64/192mg dose taken as one tablet once per day. At each monthly visit, treatment tolerance and response will be adjudicated using objective, dose-escalation criteria. At both Week 4 and Week 8, all subjects will be evaluated for dose escalation. Subjects who are demonstrating a reduction of 50% or more in CAPS-5 total score will remain in treatment with HB-1 (or Placebo) at same dose. Subjects with less than a 50% reduction in CAPS-5, who have experienced no treatment-emergent Grade 3 or higher adverse event related to study drug since the prior visit, will be dose-escalated to the 86/258mg telmisartan/verapamil extended dose. After escalation, subjects will remain on higher dose throughout the remainder of the study.

  • PlaceboDrug

    Matching Placebo will be dispensed to analogous subjects in Placebo group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To measure the efficacy of HB-1 on clinician-rated symptoms of Post-Traumatic Stress Disorder in male and female adults (age 18 to 65 years) with Post-Traumatic Stress Disorder.Time frame: Baseline, Week 4, Week 8 and Week 12.

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Paratus Clinical Research Canberra

    Deakin, Australian Capital Territory, Australia · Recruiting

  • Novatrials

    Charlestown, New South Wales, Australia · Recruiting

  • East Sydney Doctors

    Darlinghurst, New South Wales, Australia · Recruiting

  • Innovate Clinical Research

    Waitara, New South Wales, Australia · Recruiting

  • WSLHD Mental Health Services, Westmead Hospital

    Westmead, New South Wales, Australia · Recruiting

  • Paratus Clinical Research Brisbane

    Herston, Queensland, Australia · Recruiting

  • Mackay Hospital and Health Service

    Mackay, Queensland, Australia · Recruiting

  • University of the Sunshine Coast Clinical Trials, Morayfield

    Morayfield, Queensland, Australia · Recruiting

  • Ramsay Clinic New Farm

    New Farm, Queensland, Australia · Recruiting

  • University of the Sunshine Coast Clinical Trials, Sippy Downs

    Sippy Downs, Queensland, Australia · Recruiting

  • South Australian Health and Medical Research Institute

    Adelaide, South Australia, Australia · Recruiting

  • NeuroCentrix

    Carlton, Victoria, Australia · Recruiting

  • Peninsula Therapeutic and Research Group

    Frankston, Victoria, Australia · Recruiting

  • Monash Alfred Psychiatry Research Centre

    Melbourne, Victoria, Australia · Recruiting

  • Ramsay Clinic Albert Road

    Melbourne, Victoria, Australia · Recruiting

  • Paratus Clinical Research Melbourne

    Northcote, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.